Clinical Trial Update: Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of ramucirumab plus irinotecan in previously treated advanced gastric or gastroesophageal junction adenocarcinoma has completed and posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Camptosar (irinotecan)
• Cyramza (ramucirumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-11